Published in Cancer Weekly, November 22nd, 2005
OGX-011 is a second-generation antisense drug designed to specifically inhibit the production of clusterin, a cell-survival protein associated with resistance to standard anticancer treatments. This clinical trial is designed to assess the safety and efficacy of OGX-011 in combination with docetaxel in women with metastatic or locally advanced breast cancer. OncoGenex is developing OGX-011 in collaboration with Isis Pharmaceuticals Inc. (ISIS).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.